Clinical Trial Update: A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial of nivolumab in unresectable stage III/IV melanoma after anti-CTLA-4 treatment; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-20